Advanced search    

Search: authors:"Luis Masana"

6 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia

hypercholesterolaemia Lipidology Lomitapide Low-density lipoprotein cholesterol Paediatric Real-world data Patient cases  Tawfeg Ben-Omran, Luis Masana, Genovefa Kolovou, Gema Ariceta, F. Javier Nóvoa, Allan M. Lund ... authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Disclosures Luis Masana received lectures and

Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases

Background PCSK9 inhibition is a new powerful cholesterol-lowering strategy. Recently, it was reported that CETP inhibitors influence PCSK9 levels as an off-target effect. We explored the relationship between circulating PCSK9 levels and CETP activity in patients with metabolic disease who were not on lipid-lowering therapy. Methods Plasma CETP activity and PCSK9 levels were...

AICAR Protects against High Palmitate/High Insulin-Induced Intramyocellular Lipid Accumulation and Insulin Resistance in HL-1 Cardiac Cells by Inducing PPAR-Target Gene Expression

-Calvo,1 Manuel Vázquez-Carrera,2 Luis Masana,3 and Dietbert Neumann1 1Department of Molecular Genetics, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht

Pitavastatin in cardiometabolic disease: therapeutic profile

Statins effectively lower low-density lipoprotein-cholesterol (LDL-C) and reduce cardiovascular risk in people with dyslipidemia and cardiometabolic diseases such as Metabolic syndrome (MetS) or type 2 diabetes (T2D). In addition to elevated levels of LDL-C, people with these conditions often have other lipid-related risk factors, such as high levels of triglycerides, low levels...

Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention

Joan Rubiés-Prat 6 Luis Felipe Pallardo 5 Luis Masana 4 Alipio Mangas 9 Antonio Hernández-Mijares 8 Pedro González-Santos 2 Juan F Ascaso 10 Juan Pedro-Botet 11 0 Solvay Pharma , Barcelona , Spain 1

Familial hypercholesterolemia in Morocco: first report of mutations in the LDL receptor gene

Familial hypercholesterolemia (FH) is a genetic disorder mainly caused by defects in the low-density lipoprotein receptor (LDLR) gene, although it can also be due to alterations in the gene encoding apolipoprotein B (familial defective apoB or FDB) or in other unidentified genes. In Morocco, the molecular basis of FH is unknown. To obtain information on this issue, 27 patients...